Understanding the Clinical Challenge Behind Rapid Preeclampsia Biomarker Testing

Pre-eclampsia is a multisystem disorder that can occur after 20 weeks of gestation and remains a major cause of maternal and fetal/neonatal morbidity and mortality worldwide. One of the persistent difficulties in managing this condition is early detection: elevated soluble fms-like tyrosine kinase-1 (sFlt-1) and decreased placental growth factor (PlGF) are known to predict subsequent pre-eclampsia, yet these biomarker levels vary by gestational age and pregnancy type. This variability means clinicians need testing tools that not only deliver quantitative data quickly but also support interpretation across different clinical contexts.

Nanjing Poclight Biotechnology Co., Ltd., operating under the brand Poclight, has positioned itself as a supplier of point-of-care maternal-fetal diagnostic tools for pre-eclampsia risk assessment. The company's approach combines biomarker interpretation with a portable dry micro analyzer, addressing the dual need for speed and clinical context in obstetric testing environments.

The Pregnancy Care Solution: Combining sFlt-1 and PlGF Measurement

At the center of Poclight's offering is the Pregnancy Care — Pre-eclampsia Assessment Solution, built on quantitative measurement of sFlt-1 and PlGF and calculation of the sFlt-1/PlGF ratio. This solution is intended to support the assessment of suspected pre-eclampsia together with other diagnostic and clinical information, rather than functioning as a standalone diagnostic answer.

Poclight's PlGF and sFlt-1 assays are designed for quantitative determination in human serum and plasma and can be used together to determine the sFlt-1/PlGF ratio. The underlying biological logic is straightforward: as sFlt-1 increases and PlGF decreases, the sFlt-1/PlGF ratio rises, reflecting the angiogenic imbalance associated with uteroplacental dysfunction. Poclight positions this ratio as an aid in the diagnosis of pre-eclampsia when interpreted alongside other clinical findings.

Gestational Age and Pregnancy-Type Awareness

A distinguishing feature of Poclight's clinical framework is its attention to gestational age and pregnancy type. PlGF and sFlt-1 concentrations vary across gestation, so biomarker interpretation should account for the stage of pregnancy. Equally important, biomarker profiles differ between singleton and multiple pregnancies, meaning thresholds established in singleton pregnancies should not be automatically extrapolated to twin pregnancies. Poclight's knowledge base explicitly states that singleton-derived clinical thresholds should not be assumed applicable to twin pregnancies, reflecting a cautious, evidence-based interpretive stance.

Referencing Published Clinical Thresholds

Poclight's materials reference external, published clinical evidence to contextualize how sFlt-1/PlGF ratios are used in practice. For example, published NICE guidance for the Elecsys sFlt-1/PlGF assay outlines rule-out and rule-in cut-offs that differ by gestational window—one set of thresholds for 20+0 to 33+6 weeks and another for ≥34+0 weeks to birth. Separately, the PROGNOSIS study validated a ratio of 38 for short-term prediction in singleton pregnancies with suspected pre-eclampsia, reporting a negative predictive value of 99.3% for ruling out pre-eclampsia within one week when the ratio is ≤38. Poclight is careful to note that these are external published thresholds generated using other assay platforms and are not described as Poclight-specific performance data unless independently validated—an important distinction for clinical accuracy.

Poclight also references published PlGF-based testing frameworks, such as NICE's listed interpretation for the Triage PlGF Test, where results below 12 pg/mL are considered highly abnormal and results at or above 100 pg/mL are considered normal. Again, these are presented as external reference points rather than claims about Poclight's own assay performance.

The C5000 Dry Micro System: Engineering for Speed and Portability

Supporting the biomarker assays is Poclight's C5000 Dry Micro System, a compact analyzer engineered for rapid point-of-care testing. The system addresses several practical pain points in clinical settings: long turnaround times that delay decisions, complex liquid paths and magnetic bead separation that raise maintenance and consumable costs, and limited portability that restricts use in space-constrained settings.

The C5000 responds to these challenges with a set of defined technical metrics:

• Initial sample result in 3 minutes, supported by 7-channel operation for quick availability of results.
• Throughput of 80 tests per hour, supporting clinical workload demands.
• Accuracy with CV <3%, indicating low test variability.
• Weight of ≤8.5 kg, enabling portable, point-of-care deployment.
• Semi-automatic, portable design with touch screen operation, simplifying workflow for laboratory and clinical staff.
• Reagent flexibility, with formats available in lyophilized form for room temperature storage and transport, as well as in liquid form—reducing dependence on cold-chain logistics.
• LIS/HIS connectivity, supporting real-time information sharing with hospital information systems.

Notably, the system's architecture eliminates magnetic beads and complex liquid paths in favor of wash-free separation, which reduces consumable use and simplifies maintenance—a meaningful consideration for facilities managing testing volume alongside operational costs.

Where This Combination Fits in Clinical Practice

Poclight's Pregnancy Care solution and C5000 system are designed to work together across several settings, including clinical laboratories, hospital obstetrics and gynecology departments, and broader point-of-care testing environments. The combination of quantitative sFlt-1 and PlGF measurement with a portable, rapid-turnaround analyzer addresses a specific clinical need: providing timely angiogenic biomarker information without requiring extensive laboratory infrastructure.

The company's technical highlights also address gestational biomarker trends more broadly. In normal pregnancy, PlGF generally increases through early and mid-gestation before declining toward term, while sFlt-1 typically rises later in pregnancy. In pregnancies developing pre-eclampsia, PlGF concentrations may be lower than in uncomplicated pregnancies, while sFlt-1 may rise earlier or to a greater extent—producing the elevated sFlt-1/PlGF ratio pattern associated with greater angiogenic imbalance. Poclight is transparent that these gestational trend patterns should be treated as biological illustrations rather than exact clinical reference ranges unless numerical intervals have been directly validated for the applicable assay.

A Measured, Evidence-Referenced Approach

What distinguishes Poclight's presentation of its Pregnancy Care and C5000 Dry Micro System offerings is the consistent qualification of clinical claims. Published thresholds and study results—whether from NICE guidance or the PROGNOSIS study—are clearly attributed to their original assay platforms rather than presented as Poclight-specific performance data. This distinction matters for laboratories and clinicians evaluating point-of-care tools, since assay/platform-specific thresholds are not universally interchangeable.

For institutions seeking rapid preeclampsia biomarker testing combined with portability, reagent flexibility, and hospital system connectivity, Poclight's integration of quantitative sFlt-1/PlGF measurement with the C5000 Dry Micro System offers a technically detailed, gestational-age-aware, and pregnancy-type-conscious framework for supporting—rather than replacing—comprehensive clinical assessment of suspected pre-eclampsia.

www.poclight.com
Nanjing Poclight Biotechnology Co., Ltd